Navigation Links
Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics for Alzheimer's Disease
Date:6/22/2011

NEW YORK, June 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

(Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund a drug discovery project to identify compounds that block the puringeric receptor, P2X7, which is involved in inflammation in the brain.  One of the characteristic features of Alzheimer's disease is a robust inflammatory response involving over-activation of specialized brain cells called microglia and the release of pro-inflammatory signals associated with the deposition of Alzheimer's disease plaques in the brain.  These pro-inflammatory signals are closely associated with the P2X7 receptor, putting this novel target at the heart of brain inflammation.

"Compounds that block P2X7 may treat brain inflammation and can potentially be useful in the treatment of Alzheimer's disease and other neurodegenerative diseases," said Howard Fillit, MD, Executive Director, ADDF.  "P2X7 is a novel target and we are excited to fund the program and investigate its therapeutic potential."

"We are pleased to be selected by the ADDF for this peer-reviewed grant, which recognizes the quality of our research capabilities in the challenging field of neuroinflammation." Said Stefan Lohmer, co-founder and CEO of Axxam.  "We are looking forward to working with the ADDF team and moving our Alzheimer's disease program forward."

For more information about the ADDF or to speak with Dr. Fillit, please contact Filomena Machleder at 212-901-8004 or fmachleder@alzdiscovery.org.  For more information about Axxam, please contact Stefan Lohmer, PhD, CEO, Axxam at +39 02 2105622 or stefan.lohmer.sl@axxam.com.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)
The Alzheimer's Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $50 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 19 countries. 

About Axxam SpA (www.axxam.com)
Axxam is a privately owned contract research and discovery company located at the San Raffaele Biomedical Science Park in Milan, Italy.  The company has developed a proven track record as a third party research and discovery services provider for the life science industry.  In addition, Axxam conducts several discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations.

CONTACT: Filomena Machleder, +1-212-901-8004, fmachleder@alzdiscovery.org; Stefan Lohmer, PhD, CEO, Axxam, +39-02-2105622, stefan.lohmer.sl@axxam.com


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
2. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
3. GE Discovery ST Installed at Imaging Healthcare Specialists
4. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
5. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
6. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
7. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
8. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
9. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
10. Reportlinker Adds The Drug Discovery Outsourcing Market
11. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... 17, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... and non-U.S. investors for the sale of shares ... the Company,s newly designated Series B Convertible Preferred ... expects to conduct a closing with respect to ...
(Date:8/17/2017)... 2017 Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam ... new data on Cell-Ess® Universal Titer Boost at the 9 ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international ... ... ...
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
Breaking Medicine Technology:
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... Tanya ... Exilis in Lone Tree, CO, at Atagi Plastic Surgery and Skin Aesthetics. , ... a potent combination of radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed on ...
(Date:8/17/2017)... Los Angeles, California (PRWEB) , ... August 17, 2017 , ... ... in the number of South Korean men obtaining plastic surgery, largely influenced by the ... health and beauty clinic Beverly Hills Physicians notes that standards of male appearance are ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new ... a number of changes to the smartwatch market. As of June 2017, nearly nine ... from the six months prior. Additionally, according to latest WEAR Report Industry Overview and ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses ... encourage inner healing of memories and achieve forgiveness, through a progressive journey toward ...
(Date:8/17/2017)... ... August 17, 2017 , ... CareAcademy, a provider of ... raised $1.675 M in seed funding to further expand its course portfolio and ... Capital Fund are the company’s primary investors. , Founded in 2016, ...
Breaking Medicine News(10 mins):